🚀 VC round data is live in beta, check it out!
Renalytix Valuation Multiples
Discover revenue and EBITDA valuation multiples for Renalytix and similar public comparables like Spineguard, Allurion, Jana Medical Company, Scandinavian ChemoTech and more.
Renalytix Overview
About Renalytix
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
Founded
2018
HQ
Employees
46
Website
Financials (LTM)
EV
$11M
Renalytix Financials
Renalytix reported last 12-month revenue of $3M.
In the same LTM period, Renalytix generated had net loss of ($20M).
Revenue (LTM)
Renalytix P&L
In the most recent fiscal year, Renalytix reported revenue of $3M and EBITDA of ($21M).
Renalytix expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | $3M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $1M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 40% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($21M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (710%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (573%) | XXX | XXX | XXX |
| Net Profit | ($20M) | XXX | ($20M) | XXX | XXX | XXX |
| Net Margin | (680%) | XXX | (680%) | XXX | XXX | XXX |
| Net Debt | — | — | $5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Renalytix Stock Performance
Renalytix has current market cap of $12M, and enterprise value of $11M.
Market Cap Evolution
Renalytix's stock price is $0.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11M | $12M | -0.4% | XXX | XXX | XXX | $-0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRenalytix Valuation Multiples
Renalytix trades at 3.7x EV/Revenue multiple, and (0.5x) EV/EBITDA.
EV / Revenue (LTM)
Renalytix Financial Valuation Multiples
As of April 18, 2026, Renalytix has market cap of $12M and EV of $11M.
Equity research analysts estimate Renalytix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Renalytix has a P/E ratio of (0.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12M | XXX | $12M | XXX | XXX | XXX |
| EV (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.5x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 9.3x | XXX | XXX | XXX |
| P/E | (0.6x) | XXX | (0.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Renalytix Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Renalytix Margins & Growth Rates
Renalytix's revenue in the last fiscal year grew by 13%.
Renalytix's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Renalytix Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (710%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (14%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 163% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 30% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 613% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Renalytix Public Comps
See public comps and valuation multiples for other Health Data & Analytics and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Renalytix | XXX | XXX | XXX | XXX | XXX | XXX |
| Spineguard | XXX | XXX | XXX | XXX | XXX | XXX |
| Allurion | XXX | XXX | XXX | XXX | XXX | XXX |
| Jana Medical Company | XXX | XXX | XXX | XXX | XXX | XXX |
| Scandinavian ChemoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcoma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Renalytix M&A Activity
Renalytix acquired XXX companies to date.
Last acquisition by Renalytix was on XXXXXXXX, XXXXX. Renalytix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Renalytix
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRenalytix Investment Activity
Renalytix invested in XXX companies to date.
Renalytix made its latest investment on XXXXXXXX, XXXXX. Renalytix invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Renalytix
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Renalytix
| When was Renalytix founded? | Renalytix was founded in 2018. |
| Where is Renalytix headquartered? | Renalytix is headquartered in United Kingdom. |
| How many employees does Renalytix have? | As of today, Renalytix has over 46 employees. |
| Who is the CEO of Renalytix? | Renalytix's CEO is James Renwick McCullough. |
| Is Renalytix publicly listed? | Yes, Renalytix is a public company listed on London Stock Exchange. |
| What is the stock symbol of Renalytix? | Renalytix trades under RENX ticker. |
| When did Renalytix go public? | Renalytix went public in 2018. |
| Who are competitors of Renalytix? | Renalytix main competitors are Spineguard, Allurion, Jana Medical Company, Scandinavian ChemoTech. |
| What is the current market cap of Renalytix? | Renalytix's current market cap is $12M. |
| What is the current revenue of Renalytix? | Renalytix's last 12 months revenue is $3M. |
| What is the current EV/Revenue multiple of Renalytix? | Current revenue multiple of Renalytix is 3.7x. |
| Is Renalytix profitable? | No, Renalytix is not profitable. |
| What is the current net income of Renalytix? | Renalytix's last 12 months net income is ($20M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.